CSE’s Barrington Miller is joined by Iris Bincovich, CEO of InnoCan Pharma (CSE:INNO) to discuss the company’s focus as a specialty pharmaceutical company including the development of products that harness the unique properties of Cannabinoids combined with smart delivery formulations. The conversation also highlights the importance – and impact – that achieving milestones has had on the company’s life as a public company.
Here’s an overview of what Barrington and Iris discuss in this edition of the “Exchange for Entrepreneurs” podcast:
0:00 – Re-introducing Iris Bincovich and Innocan Pharma
3:31 – Iris’ background in chemistry and the healthcare industry
5:22 – Exporting Israeli innovation across the globe
8:41 – Going public in Canada and the importance of meeting milestones
13:47 – Opportunities for growth in 2022
16:19 – Accessing Innocan’s products
18:35 – Iris’ favourite restaurant
About InnoCan Pharma Corporation
The Corporation’s business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products; (ii) research and development of non-pharmaceutical products for third parties in exchange for fees and/or royalties; and (iii) research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales.
Learn more about InnoCan Pharma at InnoCan Pharma Corporation | CSE – Canadian Securities Exchange (thecse.com)
This week we take the show on-the-road to Tel Aviv, Israel where we get caught up with tech executives in the health tech, cannabis, life sciences and food tech sectors. First-up is an intro to VVT Medical led by Erez Tetro and Concenter BioPharma, led by Dror Chevion. After introducing their respective businesses Erez and…
(CSE:ATL)
CBD is advertised as providing relief for anxiety, depression and post-traumatic stress disorder, among other benefits. Its popularity reflects, in part, that it is positioned as non-psychoactive while still providing access to many aspects of the cannabis plant that are good for human health. The challenge is to create a more precise and efficient method…
CSE’s Barrington Miller recently chatted with Iris Bincovich, the CEO of InnoCan Pharma Corporation (CSE:INNO) to discuss their recent patent application. In this chat, Iris shares how her team is designing CBD-loaded exosomes for targeting Coronavirus infected lung cells (2:15), how to improve CBD delivery through an injectable solution (7:53), and her prospects concerning a…
